Evidence map›Paper›PMID 40244389›Full record

ArticleJournal of neural transmission (Vienna, Austria : 1996)2025

Identification of DAGLB variants in Japanese early-onset Parkinson's disease.

Yue Luo, Manabu Funayama, Taku Hatano, Yuanzhe Li, Hiroyo Yoshino, Satoshi Yamashita, Akira Mori, Ryoichi Nakamura, Yoshio Hashizume, Mari Yoshida and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neural transmission (Vienna, Austria : 1996), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yue LuoDepartment of Neurology, Faculty of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Manabu FunayamaDepartment of Neurology, Faculty of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. funayama@juntendo.ac.jp.ORCID 0000-0002-7412-3631
Taku HatanoDepartment of Neurology, Faculty of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Yuanzhe LiDepartment of Neurology, Faculty of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Hiroyo YoshinoResearch Institute for Diseases of Old Age, Graduate School of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Satoshi YamashitaDepartment of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Akira MoriDepartment of Neurology, Kumamoto Southern Regional Hospital, Kumamoto, Japan.
Ryoichi NakamuraDepartment of Neurology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Aichi, Japan.
Yoshio HashizumeChoju Medical Institute, Fukushimura Hospital, Toyohashi, Aichi, Japan.
Mari YoshidaInstitute for Medical Science of Aging, Aichi Medical University, Nagakute, Aichi, Japan.
Yuichi RikuInstitute for Medical Science of Aging, Aichi Medical University, Nagakute, Aichi, Japan.
Naomi KanzatoDepartment of Neurology, Okinawa Prefectural Southern Medical Center & Children's Medical Center, Haebaru-cho, Okinawa, Japan.
Nobutaka HattoriDepartment of Neurology, Faculty of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. nhattori@juntendo.ac.jp.

Funding

Japan Agency for Medical Research and Development 23bm1423015h0001Japan Agency for Medical Research and Development 24ek0109677h0002Japan Agency for Medical Research and Development JP23dm0207070Japan Agency for Medical Research and Development JP23dm0307101Japan Society for the Promotion of Science 21H04820Japan Society for the Promotion of Science 21K07283Japan Society for the Promotion of Science 22K07542Japan Society for the Promotion of Science 23K06958Japan Society for the Promotion of Science 24H00068Japan Society for the Promotion of Science 24K02372Juntendo University N/AMoonshot Research and Development Program JPMJMS2024-5Promotion and Mutual Aid Corporation for Private Schools of Japan N/A
6 · The paper itself

Abstract

Hereditary factors play a significant role in the development of Parkinson's disease and the identification of causative genes is ongoing. Biallelic variants in Diacylglycerol lipase β (DAGLB) are related to early-onset Parkinson's disease (EOPD) in the Chinese population, and have also been identified in an Algerian case. To date, no EOPD cases with DAGLB variants have been reported among Japanese patients. This study was conducted to clarify the occurrence of DAGLB variants among Japanese EOPD patients. We screened 270 patients with sporadic EOPD (male: female ratio, 1.37:1; mean age at onset ± standard deviation, 37.32 ± 7.91 years), and 276 patients with suspected autosomal recessive Parkinson's disease (ARPD, male: female ratio, 0.75:1; mean age at onset ± standard deviation, 58.86 ± 14.67 years). Genetic screening of all coding exons and flanking splicing regions was performed by Sanger sequencing. We identified two rare biallelic variants in two patients, both from consanguineous families. One variant was a homozygous frameshift variant (c.1770_1771del, p.Tyr591ProfsTer26), which was predicted to be pathogenic. The other was a missense variant (c.1444T > C, p.Tyr482His) and was predicted to be benign, with co-segregation ruled out for this variant. We identified a pathogenic variant in the DAGLB gene. Together with previous reports, these findings provide further evidence that loss-of-function variants in DAGLB are involved in EOPD in the Japanese population.

Indexed as

Lipoprotein LipaseParkinson DiseaseAdultAgedAge of OnsetEast Asian PeopleFemaleHumansJapanMaleMiddle AgedLipoprotein LipaseDiacylglycerol lipase ΒDNA sequence analysisFrameshift mutationParkinson’s disease

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.